AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Biological therapies such as BCG use different ways to stimulate
the immune system and stop cancer cells from growing. It is not yet known whether AD 32 is
more effective with or without BCG after surgery for superficial bladder cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of AD 32 with or without BCG
after surgery in treating patients who have newly diagnosed or recurrent superficial bladder
cancer.